NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
09 Jun 2015

AM‐Pharma receives FDA and EMA orphan drug designation to treat hypophosphatasia

Bunnik, The Netherlands, 9 June 2015. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase), today announces that the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have both granted orphan designation status to recAP for the treatment of hypophosphatasia.
27 May 2015

CVRx® Barostim Therapy® for Heart Failure Clinical Trial Results Presented in the Late-Breaking Clinical Session of the ESC-Heart Failure 2015 Annual Conference

Seville– May 27, 2015 – CVRx, Inc., a private medical device company, announced that positive results from the ‘Barostim Therapy for Heart Failure’ randomized, controlled clinical trial were presented at the ESC-Heart Failure 2015 Annual Conference in a Late-Breaking Trial Session.
26 May 2015

CVRx® Barostim Therapy® for Heart Failure Clinical Trial Results Presented in the Late-Breaking Clinical Trial Session of the Heart Rhythm Society 2015 Annual Conference

Minneapolis – May 26, 2015 – CVRx, Inc., a private medical device company, announced that positive results from the ‘Barostim Therapy for Heart Failure’ randomized, controlled clinical trial were presented at the 2015 annual Scientific Sessions of the Heart Rhythm Society (HRS) in a Late-Breaking Clinical Trial Session.
FDA Grants Orphan Drug Designation to Aura Biosciences’ Novel Treatment for Uveal Melanoma<
21 May 2015

FDA Grants Orphan Drug Designation to Aura Biosciences’ Novel Treatment for Uveal Melanoma

Uveal Melanoma, also referred to as Ocular Melanoma (OM), is an aggressive form of cancer that develops in the uvea, or uveal tract, of the eye.
14 May 2015

Kala Pharmaceuticals Appoints Mark Iwicki as Executive Chairman

WALTHAM, Mass., May 14, 2015 -- Kala Pharmaceuticals, Inc. (Kala), a developer of innovative ophthalmic products based on its proprietary mucus penetrating particle (MPP) technology, today announced the appointment of Mark Iwicki as Executive Chairman and a member of its board of directors.
13 May 2015

Pfizer Acquires Minority Interest in AM-Pharma; Secures Option to Acquire Company

Bunnik, The Netherlands, and New York, NY – 11 May 2015 – AM‐Pharma B.V., a privately held Dutch biopharmaceutical company focused on the development of recombinant human Alkaline Phosphatase (recAP ) for inflammatory diseases, and Pfizer Inc. (NYSE: PFE) announced today that Pfizer has acquired a minority equity interest in AM-Pharma and secured an exclusive option to acquire the remaining equity in the company.
02 Apr 2015

Kala Pharmaceuticals Announces Positive Results from Phase 2 Trial of KPI-121 in Dry Eye Disease

WALTHAM, Mass., April 1, 2015 -- Kala Pharmaceuticals, Inc. (Kala), a developer of innovative ophthalmic products based on its proprietary mucus-penetrating particle (MPP) technology, today announced positive top-line results from a Phase 2 clinical trial of KPI-121, its nanoparticle loteprednol etabonate MPP product candidate, in patients with dry eye disease.
01 Apr 2015

Kala Pharmaceuticals Announces Positive Results from Phase 3 Trial of KPI-121 in Cataract Surgery

WALTHAM, Mass., April 1, 2015 -- Kala Pharmaceuticals, Inc. (Kala), a developer of innovative ophthalmic products based on its proprietary mucus penetrating particle (MPP) technology, today announced positive top-line results from a Phase 3 clinical trial of KPI-121, its nanoparticle loteprednol etabonate MPP product candidate, for the treatment of inflammation and pain in patients who had undergone cataract surgery.
17 Mar 2015

CVRx® Barostim Therapy™ for Heart Failure Clinical Trial Results Presented in a Featured Clinical Research Session of the American College of Cardiology Annual Conference

Minneapolis – March 17, 2015 – CVRx, Inc., a private medical device company, announced that positive results from the Barostim Therapy for Heartn Failure randomized, controlled clinical trial were presented at American College of Cardiology (ACC) in a Featured Clinical Research Session.
Aura Biosciences Closes $21M Series B Financing<
06 Mar 2015

Aura Biosciences Closes $21M Series B Financing

Aura Biosciences’ platform is based on viral nanoparticles, a new class of drugs that harness the potential of a unique cell targeting for the treatment of cancer. 

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка